0V0 Stock Overview
Engages in the animal health business worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Vimian Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.80 |
| 52 Week High | SEK 4.12 |
| 52 Week Low | SEK 2.11 |
| Beta | 1.6 |
| 11 Month Change | -2.56% |
| 3 Month Change | 4.68% |
| 1 Year Change | 76.58% |
| 33 Year Change | -47.37% |
| 5 Year Change | n/a |
| Change since IPO | -57.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0V0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 6.3% | 2.4% | 0.8% |
| 1Y | 76.6% | -5.0% | 9.1% |
Return vs Industry: 0V0 exceeded the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: 0V0 exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 0V0 volatility | |
|---|---|
| 0V0 Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0V0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 0V0's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1,100 | Patrik Eriksson | vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
| 0V0 fundamental statistics | |
|---|---|
| Market cap | €1.99b |
| Earnings (TTM) | €256.00k |
| Revenue (TTM) | €352.39m |
7,760x
P/E Ratio5.6x
P/S RatioIs 0V0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0V0 income statement (TTM) | |
|---|---|
| Revenue | €352.39m |
| Cost of Revenue | €105.67m |
| Gross Profit | €246.72m |
| Other Expenses | €246.46m |
| Earnings | €256.00k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 0.00049 |
| Gross Margin | 70.01% |
| Net Profit Margin | 0.073% |
| Debt/Equity Ratio | 35.9% |
How did 0V0 perform over the long term?
See historical performance and comparison